2CURRAN M, NOBLE S. Valganciclovir [J]. Drugs, 2001, 61(8): 1145-1150.
3SUGAWARA M, HUANG W, FEI YJ, et al. Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2 [J]. J Pharm Sci, 2000, 89(6): 781-789.
4JUNG D, DORR A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV- seropositive subjects [J]. J Clin Pharmacol,1999, 39(8) : 800-804.
5BROWN F, BANKEN L, SAYWELL K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV- seropositive volunteers [J]. Clin Pharmacokinet, 1999, 37(2): 167-176.
6PESCOVITZ MD, RABKIN J, MERION RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients [J]. Antimicrob Agents Chemother, 2000, 44(10) : 2811-2815.
7MARTIN DF, SIERRA-MADERO J, WALMSLEY S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis [J]. N Engl J Med, 2002, 346(15) : 1119-1126.
